Arevipharma offers a broad range of synthetic, generic active ingredients in various volume, indication and substance classes. All active ingredients are produced at the site in Radebeul under cGMP conditions and are already registered in many global pharmaceutical markets. In consultation with our customers, we also regularly tackle registration projects in countries that are additionally required for their marketing strategy, at short notice and reliably.
Narcotics represent an important part of our portfolio of active ingredients. Arevipharma can handle all classes of these active ingredients without any restrictions on their volumes. This makes us one of the largest producers of narcotics in the world.
Active pharmaceutical ingredients
Controlled Substances
| Product | Indication | Regulatory Documentation |
|---|---|---|
| Amfepramone HCl | Appetite depressant | US-DMF, ASMF |
| Arketamine HCl* | Antidepressant | ASMF |
| Buprenorphine | Analgesic, OUD | CEP, US-DMF, ASMF |
| Buprenorphine HCl | Analgesic | CEP, US-DMF, ASMF |
| Esketamine HCl* | Analgesic, Antidepressant | CEP, US-DMF, ASMF |
| Fentanyl | Analgesic | CEP, ASMF |
| Fentanyl Citrate | Analgesic | CEP, ASMF |
| Ketamine HCl* | Analgesic | CEP, US-DMF, ASMF |
| Remifentanil HCl | Analgesic | CEP, ASMF |
| Tilidine HCl HH | Analgesic | CEP, ASMF |
*not a controlled substance in several countries (e.g. Germany)
Other APIS
| Product | Indication | Regulatory Documentation |
|---|---|---|
| Amiodarone HCl | Antiarrhythmic | CEP, ASMF |
| Bisoprolol Fumarate | Antihypertensive, Beta blocker | CEP, US-DMF, J-DMF, ASMF |
| Cafedrine HCl | Cardiac Stimulant | ASMF |
| Cannabidiol | Various | ASMF |
| Carbamazepine | Anticonvulsant | CEP, ASMF |
| Cetirizine 2HCl | Antihistamine | CEP, ASMF |
| Dimethylfumarate | Psoriasis, Multiple Sclerosis | US-DMF, ASMF |
| Doxapram HCl | Analeptic | CEP, US-DMF, J-DMF |
| Ebastine | Antihistamine | CEP, ASMF |
| Phenprocoumon | Anticoagulant | ASMF |
| Phytosterol | Urological diseases | ASMF |
| Pyridostigmine Bromide | Parasympathomimetic | CEP, ASMF |
| Rivastigmine | Alzheimer’s disease | CEP submitted |
| Sotalol HCl | Antiarrhythmic, Beta blocker | CEP, ASMF |
| Sultiame | Anticonvulsant | ASMF |
| Theodrenaline HCl | Cardiac Stimulant | ASMF |
| Torasemide | Diuretic | CEP, ASMF, J-DMF |
R&D PRODUCTS
| Product | Indication | Status |
|---|---|---|
| Naloxone HCl DH | Opiod Antagonist, Alcohol dependence | Validation ongoing |
| Naltrexone (HCl) | Opiod Antagonist, OUD | Validation ongoing |
| Rivastigmine Tartrate | Alzheimer’s disease | Validation ongoing |
| Oxymorphon | Analgesic, Intermediate | Pilot scale |
| Folinic Acid (Calcium Folinate, Leucovorin) | Rescue Agent | Validation 2026 |
| Tirbanibulin | Keratosis | Validation 2026 |
| Nalbuphine HCl | Analgesic, partial antagonist | Validation 2027 |
| Nalmefene HCl | Opiod Antagonist | Validation 2027 |
| Sufentanil | Analgesic | Laboratory Assessment |
| Tivozanib | Anticancer | Laboratory Assessment |
| Vismodegib | Anticancer | Laboratory Assessment |
| Alpelisib | Anticancer | Under Evaluation |
| Diroximel Fumarate | Multiple Sclerosis | Under Evaluation |
| Droperidol | Antiemetic | Under Evaluation |
| Remimazolam | Analgesic | Under Evaluation |
